Repeat CT scan three months later showed necrosis within multiple tumors, however the patient developed a new 3.2 cm × 2.3 cm lesion consistent with progression

of disease. Imatinib was stopped and the patient was started on sunitinib 50 mg four weeks on and two weeks off. While on sunitinib, he developed significant anemia with hemoglobin of 4.9 requiring admission to Inhibitors,research,lifescience,medical the hospital and multiple transfusions. Work-up revealed Coombs positive autoimmune hemolytic anemia managed with steroids. Additionally he developed new bilateral lower extremity DVTs while on coumadin and an IVC filter was placed. CT scan during that admission showed progression of disease. Sunitinib was stopped and he began treatment with sorafenib 400 mg twice daily. CT scans after three Inhibitors,research,lifescience,medical months of

treatment showed marked decrease in size of the primary tumor (Figure 2), but follow-up CT scans after six months on sorafenib revealed a new soft tissue mass in the left lower abdomen, as well as enlargement and necrosis of multiple soft tissue masses along the right paracolic gutter. There was also decrease Inhibitors,research,lifescience,medical in two masses in the right lower quadrant. At that time imatinib, 400 mg every other day was added to sorafenib 400 mg twice daily. Follow-up CT scans showed stable disease for almost one year after which he developed numerous peritoneal lesions (Figure 3). Imatinib was increased to 400 mg daily and surveillance CT scans have since remained stable over the last one year using combination treatment of imatinib and sorafenib. Figure 2 CT scan after three months of sorafenib 400 mg twice daily. Figure 3 CT scan while on sorafenib and imatinib combination therapy. Discussion While a relatively rare gastrointestinal Inhibitors,research,lifescience,medical malignancy, GISTs are the most common primary mesenchymal tumor arising in the GI tract. Eighty five to ninety percent of all GISTs Inhibitors,research,lifescience,medical arise in the stomach and small intestine and approximately 4% arise in the rectum (1). This group of tumors is believed to be derived from the interstitial cells of Cajal, which are responsible for coordinating BYL719 cell line peristaltic contractions throughout the GI tract.

Studies have demonstrated that these cells commonly express KIT tyrosine kinase (CD117). Sixty eight percent of mutations to KIT occur in the juxtamembrane portion (exon 11) while only 1% are believed to occur in exon 17 (2). Surgical resection remains the only potential curative treatment of GIST. However, recurrence Idoxuridine rates following surgical resection have been reported from 40-90% (3). Understanding of the molecular oncogenesis of GIST has prompted investigations in the use of targeted therapy to block the function of this tyrosine kinase. The first of these medications, imatinib produced significant responses with median progression free survival in the US S0033 phase 3 trial of 18 months and median overall survival of 55 months (4).